InnoPep

Executive Summary

InnoPep Inc. is a San Diego-based biotechnology company founded in 2017 that specializes in custom peptide synthesis and conjugation services for the research community. The company offers high-quality long peptides up to 100 amino acids, modified peptides including stapled peptides, glycopeptides, and dye-labeled peptides, serving as a contract research organization (CRO) for academic and biotech researchers in oncology and immunology. As a private service provider, InnoPep does not develop its own drug pipeline but enables others by supplying critical reagents. Its focus on complex peptide modifications positions it in a niche but growing market, driven by increasing demand for peptide-based therapeutics and research tools. The company's business model as a CRO provides recurring revenue streams from repeat customers, but it also limits direct exposure to drug development risks. InnoPep likely benefits from the broader trend of outsourcing peptide synthesis to specialized providers. However, competition from larger CROs and in-house capabilities of some clients may cap growth. Given its private status and lack of disclosed financials, the investment conviction is moderate. Key upcoming catalysts could include announcements of new large-scale contracts, expansion into novel peptide chemistries (e.g., cyclic peptides), or strategic partnerships with pharmaceutical companies seeking custom reagents for immuno-oncology programs.

Upcoming Catalysts (preview)

• Q4 2026Major Contract Win with Top-Tier Biotech or Pharma40% success
• Q2 2027Expansion into Cyclic Peptide or Macrocyclic Synthesis Services30% success
• Q1 2027Strategic Partnership for Peptide Conjugation Technologies35% success